IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trialBrian I. Rini, Tim Eisen, Stéphane Oudard et al.|The Lancet Oncology|2016Cited by 218
An Interim Analysis of the Brain Health & the Microbiome Proof-of-Concept Study in Patients With Mild Cognitive ImpairmentLindsey Gordon, Leigh A. Frame, Alison Warren et al.|Current Developments in Nutrition|2025Cited by 0